Tarsus Q3 2026 Sales Surge 64% to $194.6M
Tarsus reported a 64% year-over-year increase in net product sales for Q3 2026, surpassing $1 billion in cumulative sales. This robust growth underscores Tarsus' leading position in the Demodex blepharitis treatment market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed